KRAS Inhibitor Heterocyclic Compounds for Cancer Treatment

USPTO published patent application US20260092075A1 disclosing KRAS inhibitor heterocyclic compounds for cancer treatment. The application claims compounds with specific structural formulas (A, B, R1, R2, R3a, R3b, Z1, Z2, Z3 as described), their pharmaceutically acceptable salts, and associated treatment methods. CPC classifications indicate primary focus on C07D chemistry (heterocyclic compounds), A61K pharmaceutical compositions, and A61P antineoplastic agents.

This is a patent application publication with no regulatory compliance requirements. Pharmaceutical and biotech companies researching KRAS oncological targets may review the claimed compound structures to assess freedom-to-operate considerations or identify potential licensing opportunities. No immediate action is required by regulated entities.